RBC Capital Maintains Outperform on Praxis Precision Medicine, Raises Price Target to $478
Wedbush Maintains Underperform on Praxis Precision Medicine, Raises Price Target to $189
Praxis Precision Medicines (NASDAQ:PRAX) Narrows Q3 Loss Ahead of Two FDA Decisions
Loading...